Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUZALLO vs ULORIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DUZALLO (allopurinol) is a xanthine oxidase inhibitor that reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
ULORIC (febuxostat) is a xanthine oxidase inhibitor that reduces serum uric acid levels by inhibiting the enzyme xanthine oxidase, which catalyzes the conversion of hypoxanthine to xanthine and xanthine to uric acid.
Management of signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy),Prevention of tumor lysis syndrome in patients receiving chemotherapy for leukemia, lymphoma, or solid tumor malignancies
Chronic management of hyperuricemia in patients with gout,Off-label: Prevention of tumor lysis syndrome (not FDA-approved)
Adults: 200 mg orally twice daily.
40 mg orally once daily; may increase to 80 mg once daily if serum uric acid not at target after 2 weeks.
Terminal elimination half-life is approximately 12 hours (range 10–14 hours), allowing twice-daily dosing for steady-state achievement within 2–3 days.
Terminal elimination half-life is approximately 5-8 hours. This short half-life supports once-daily dosing for maintenance of therapeutic urate-lowering effect.
Primarily metabolized by aldehyde oxidase to oxipurinol, the active metabolite. Also metabolized via xanthine oxidase. Bioactivation requires hepatic metabolism.
Primarily metabolized by UGT1A1, UGT1A3, UGT1A9, and CYP2C8; minor metabolism by CYP1A2, CYP2C9, and CYP2D6. Approximately 22% excreted unchanged in urine.
Primarily renal excretion (approximately 70% as unchanged drug); biliary/fecal excretion accounts for about 20%; the remainder undergoes hepatic metabolism.
Renal excretion of unchanged drug accounts for approximately 40-45% of the dose. Biliary/fecal excretion eliminates about 50-55% of the dose, primarily as oxidative metabolites.
Approximately 95% bound primarily to albumin and alpha-1-acid glycoprotein.
Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of distribution is 0.3–0.5 L/kg, indicating distribution primarily into extracellular fluid and well-perfused tissues.
Apparent volume of distribution is about 50 L (approximately 0.7 L/kg). This suggests distribution into total body water and some tissue binding.
Oral bioavailability is 60%–70% (first-pass metabolism); intravenous bioavailability is 100%.
Oral bioavailability is approximately 85% (range 60-100%). Tablets are well absorbed, with food having no significant effect on overall absorption.
Not recommended in patients with severe renal impairment (e GFR < 30 m L/min/1.73 m²). No dose adjustment required for mild to moderate impairment (e GFR ≥ 30 m L/min/1.73 m²).
No dose adjustment required for mild to moderate renal impairment (GFR 30-89 m L/min). Not recommended for use in patients with severe renal impairment (GFR <30 m L/min) or end-stage renal disease on dialysis due to lack of efficacy data.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not recommended in moderate or severe hepatic impairment (Child-Pugh B or C).
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh Class A or B). Not recommended in severe hepatic impairment (Child-Pugh Class C) due to lack of data.
Safety and efficacy not established in pediatric patients (< 18 years).
Safety and efficacy not established in pediatric patients; no FDA-approved dosing.
No specific dose adjustment required; monitor renal function due to age-related decline.
No specific dose adjustment required; clinical studies included patients aged 65 and older with no overall differences in safety or efficacy observed.
There is no FDA black box warning for DUZALLO.
Increased risk of cardiovascular death compared to allopurinol in patients with gout and cardiovascular disease. Febuxostat should be used only in patients who have not responded adequately to allopurinol or have contraindications to allopurinol.
Hypersensitivity reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis,Acute gout flare upon initiation; may require prophylactic anti-inflammatory therapy,Renal impairment: dose adjustment required,Hepatic toxicity may occur,Elevated risk of skin rash with concurrent amoxicillin or ampicillin use
Cardiovascular events: Increased risk of cardiovascular death, especially in patients with pre-existing cardiovascular disease.,Gout flare: May increase frequency of gout flares during initiation; prophylaxis with NSAIDs or colchicine recommended.,Liver enzyme elevations: Monitor liver function tests; discontinue if persistent elevation or signs of liver injury.,Thyroid disorders: Can increase TSH levels; monitor thyroid function.,Renal impairment: Dose adjustment not required; limited data in severe renal impairment.,Drug interactions: Use with caution with azathioprine, mercaptopurine, or theophylline; increase risk of toxicity.
Hypersensitivity to allopurinol or any component of the formulation,Concomitant use with didanosine
History of hypersensitivity to febuxostat,Concurrent use with azathioprine, mercaptopurine, or theophylline (absolute)
Avoid grapefruit and grapefruit juice due to potential CYP3A4 inhibition increasing elagolix levels. High-fat meals may slightly increase elagolix absorption but no dose adjustment needed. No other significant food interactions reported.
No specific food interactions; however, high-purine foods (e.g., organ meats, anchovies, sardines, scallops, game meats, beer) may counteract efficacy by raising uric acid. Grapefruit juice has no known interaction with febuxostat. Avoid excessive alcohol, especially beer and spirits, as they increase urate levels.
DUZALLO (allopurinol) is generally considered low risk. First trimester: limited data, no increased malformations. Second/third trimester: no known fetal harm. However, use only if clearly needed.
Pregnancy Category C: In animal studies, febuxostat caused fetal toxicity (reduced fetal weights, increased incidence of fetal malformations) at doses equivalent to 2-4 times the human exposure. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if potential benefit justifies potential risk to fetus. First trimester: limited data; second and third trimesters: theoretical risk of uric acid reduction impacting fetal growth due to role of uric acid in fetal development.
Allopurinol and its metabolite oxypurinol are excreted into breast milk. M/P ratio: 1.4 for allopurinol, 2.5 for oxypurinol. No adverse effects reported in infants; compatible with breastfeeding, but monitor infant for rash.
Excretion in human milk unknown; M/P ratio not determined. Because many drugs are excreted in human milk and potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue drug, taking into account importance of drug to mother.
No specific dose adjustments recommended for pregnancy. Monitor renal function; reduce dose if creatinine clearance decreases. Standard adult dosing: 100-300 mg/day, may be increased up to 800 mg/day under guidance.
No specific dose adjustments recommended for pregnancy due to lack of pharmacokinetic data. Physiological changes in pregnancy (increased plasma volume, renal blood flow, and glomerular filtration rate) may reduce serum uric acid levels; however, no dose modification studies have been conducted. Use lowest effective dose if treatment necessary.
DUZALLO (elagolix/estradiol/norethindrone acetate) is a Gn RH antagonist combination product for management of heavy menstrual bleeding in premenopausal women with uterine leiomyomas. Monitor bone mineral density with prolonged use beyond 6 months; avoid in patients with osteoporosis risk factors. Contraindicated with strong CYP3A4 inhibitors and in pregnancy. Assess for mood changes and depression. Use effective non-hormonal contraception during treatment.
ULORIC (febuxostat) is a non-purine xanthine oxidase inhibitor indicated for chronic management of hyperuricemia in gout. Avoid use in patients with ischemic heart disease or heart failure due to increased cardiovascular events in the CARES trial. Do not use in asymptomatic hyperuricemia. Titrate from 40 mg to 80 mg if serum urate target not reached. SCr monitoring is not required, but caution with severe renal impairment (Cr Cl <30 m L/min) – no data. Avoid concomitant with azathioprine, 6-mercaptopurine, or theophylline due to XO inhibition. Coadministration with NSAIDs or colchicine is safe for flare prophylaxis. Check liver enzymes periodically as ALT elevations >3x ULN occurred in 2%.
Take one tablet daily at approximately the same time with or without food.,Missing doses increases risk of pregnancy and reduces effectiveness for bleeding control.,Use effective non-hormonal contraception (e.g., condoms, copper IUD) during treatment and for 2 weeks after discontinuation.,Report severe headache, chest pain, or vision changes immediately (risk of thromboembolic events).,Notify your doctor if you suspect pregnancy or develop heavy bleeding, worsening depression, or jaundice.,Bone density may decrease; calcium and vitamin D supplementation is recommended.,Avoid grapefruit or grapefruit juice during treatment.
Take ULORIC once daily with or without food. Do not crush or chew tablets.,You may experience a gout flare when starting ULORIC; you will be prescribed medication (e.g., colchicine, NSAID) to prevent flares for at least 6 months.,Seek immediate medical attention if you develop chest pain, shortness of breath, rapid heartbeat, or sudden numbness/weakness – these may indicate a cardiovascular event.,Avoid drinking large amounts of alcohol or consuming high-purine foods (e.g., red meat, shellfish) as they can increase uric acid levels.,Tell your doctor if you have a history of heart disease, heart failure, stroke, or liver problems.,Report persistent nausea, right upper abdominal pain, dark urine, or yellowing of eyes/skin – signs of liver injury.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUZALLO vs ULORIC, answered by our medical review team.
DUZALLO is a Xanthine Oxidase Inhibitor that works by DUZALLO (allopurinol) is a xanthine oxidase inhibitor that reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.. ULORIC is a Xanthine Oxidase Inhibitor that works by ULORIC (febuxostat) is a xanthine oxidase inhibitor that reduces serum uric acid levels by inhibiting the enzyme xanthine oxidase, which catalyzes the conversion of hypoxanthine to xanthine and xanthine to uric acid.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUZALLO and ULORIC depend on the specific clinical indication. These are both Xanthine Oxidase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUZALLO is: Adults: 200 mg orally twice daily.. The standard adult dose of ULORIC is: 40 mg orally once daily; may increase to 80 mg once daily if serum uric acid not at target after 2 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUZALLO and ULORIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUZALLO is classified as Category C. DUZALLO (allopurinol) is generally considered low risk. First trimester: limited data, no increased malformations. Second/third trimester: no known fetal harm. However, use only if. ULORIC is classified as Category C. Pregnancy Category C: In animal studies, febuxostat caused fetal toxicity (reduced fetal weights, increased incidence of fetal malformations) at doses equivalent to 2-4 times the h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.